進行非小細胞肺癌に対するMitomycin C,Videsine,Cisplatinによる他剤併用療法(MVC療法)の第2相試験  [in Japanese] Phase II Trial of Mytomycin C Plus Vindesine plus Cisplatin(MVC regimen)for Advanced Non-Small Cell Lung Cancer : Is"Non-Small Cell Lung Cancer"Homogeneous?  [in Japanese]

Search this Article

Author(s)

Abstract

進行非小細胞肺癌に対するMMC+VDS+CDDP(MVC療法)のPhase II studyを多施設共同研究で行った.2年間に119例がentryされ,うち101例が完全例で,CRでなく41例がPRとなり,奏効率は41%,中間生存期間は45週であった.腺癌に対する奏効率は病期の影響を除いても扁平上皮癌と比較して有意に低かった.病期,PSによる奏効率の差は有意ではなかった.主たる副作用は骨髄抑制と消化器症状であったが,tolerableであると考えられた.

We performed a multi-institutional phase II trial of combination chemotherapy with mytomycin C(8mg / m^2, day 1), vindesine(3mg / m^2, day 1 and 6)and cisplatin(90mg / m^2, day 1)for advanced non-small cell lung cancer. Between July, 1986 and June, 1988, 119 patients were enrolled and 101 were fully evaluable. Among 101 evaluable cases, there were 59 adenocarcinomas, 27 squamous cell carcinomas, 13 large cell carcinomas, one adenosquamous cell carcinoma, and one unclassified non-small cell lung cancer. There were significantly larger number of stage IV patients in adenocarcinoma. There was no complete response and 41 partial responses. The overall response rate was 41% The response rate of adenocarcinoma was significantly lower than that of squamous cell carcinoma and large cell carcinoma(p<0.01 and p<0.05, respectively). There was significant difference in the response rate between adenocarcinoma and squamous cell carcinoma in both stage III and stage IV diseases. There was no significant difference in the response rate according to clinical stage and PS. Toxicities were manageable and tolerable. The MVC regimen showed an acceptable response rate and tolerable toxicity for advanced non-small cell lung cancer. Adenocarcinoma had less sensitivity to this regimen compared to other non-small cell lung cancer. More attention should be paid to the histological subclass of non-small cell lung cancer in future clinical trials.

Journal

  • Japanese Journal of Lung Cancer

    Japanese Journal of Lung Cancer 31, 351-357, 1991

    The Japan Lung Cancer Society

Cited by:  1

Codes

  • NII Article ID (NAID)
    110003121859
  • NII NACSIS-CAT ID (NCID)
    AN00203978
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    03869628
  • Data Source
    CJPref  NII-ELS 
Page Top